Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020538 (hypertension)
 170,190 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effects of Dextran-Benzene-Tetracarboxylate-Hemoglobin (Dex-BTC-Hb), a chemically-modified hemoglobin-based oxygen carrier, on the vascular tone were compared to those of standard solutions, i.e. the animal's own blood and a 50 milligrams albumin solution, by measuring the carotid blood flow velocity, the mean arterial pressure, the heart rate and respiratory frequency, in anesthetized Hartley guinea pigs after a hemorragic shock. Stroma-free hemoglobin induced 40% hypertension and a 110% rise in blood flow velocity immediately after injection. The velocity was still increased 38%, 3 hours after injection. The calculations of the vascular resistances showed an increase in carotid vascular tone. Dex-BTC-Hb brought about 35% hypertension for two hours with no significant modifications of the vascular tone. These effects are similar to those of the albumin solution. These results indicate that, unlike stroma-free hemoglobin, Dex-BTC-Hb does not significantly affect the vascular tone, probably because of its slight interaction with the factors that regulate vascular tone.
 ...
PMID:[Pulsed Doppler ultrasonography to measure the vasoactive effects of hemoglobin-dextran 10-benzene-tetracarboxylate, a potential erythrocyte substitute]. 864 41

The hemoglobin-based oxygen carriers (HBOC), like dextran-benzene-tetracarboxylate-hemoglobin (Dex-BTC-Hb), which are present at high concentrations in plasma disturb arterial pressure and induce hypertension. To study if the increase of mean arterial pressure (MAP) is due to the presence of cell-free hemoglobin (Hb) inside abdominal aortic wall, we followed on a model of 50% isovolemic exchange transfusion (IET) in anesthetized guinea pigs, the kinetic of Dex-BTC-Hb distribution inside abdominal aortic wall and we investigated the relationship between arterial pressure modifications and modified Hb distribution. The administration of Dex-BTC-Hb induced instantaneously an increase of MAP that reached its maximum (53% of hypertension from baseline) at 17 min after the end of the IET and was maintained maximally up to 30 min. A significantly decrease of MAP (45% of hypertension from baseline) was observed after 60 min and the baseline level was recovered at 180 min. The investigation of tissue at 17 min by confocal microscopy showed the presence of free Hb in or upon endothelial cells (EC) in intima and in vasa vasorum. At 180 min, the free Hb was found in or upon EC and inside all abdominal aortic wall meanwhile MAP recovered its basal value. These results suggest for the first time that Hb in intima seems to induce the hypertension observed upon IET but can not sustain it even if Hb stayed present in intima and in abdominal aortic wall.
 ...
PMID:Hemoglobin-based oxygen carrier distribution inside vascular wall and arterial pressure evolution: is there a relationship? 1581 35

Several reports indicated that cell-free hemoglobin induced vasoconstriction. This phenomenon was due to different pharmacological (NO trapping, vasoactive agents release and endothelial uptake...) and physical (viscosity and oxidative process of cell-free hemoglobin...) factors. We have previously showed that the blood pressure increase would be due to the presence of Dex-BTC-Hb inside arterial wall. However, we do not know how hemoglobin penetrate inside arterial wall. The objective of this study was to examine the new hypothesis of hemoglobin penetration inside arterial wall dependent of endocytosis. For this reason, an endocytosis inhibitor, cytochalasin D, was tested. We measured in anesthetized guinea pigs, the evolution of mean arterial pressure (MAP) and plasma hemoglobin concentration in presence or absence of cytochalasin D (1.6 x 10(-4) M). These measurements were carried out before and after 50% isovolemic exchange transfusion (IET) with two cell-free hemoglobins: Dex-BTC-Hb (300 kDa) and stroma-free hemoglobin (64.5 kDa). The administration of Dex-BTC-Hb or stroma-free hemoglobin induced an immediate increase in MAP that peaked within 17 min after IET and returned to baseline after 120 min. cytochalasin D attenuated the elevation of MAP when administrated before Dex-BTC-Hb but not when administrated before stroma-free hemoglobin. Furthermore, without cytochalasin D, plasma hemoglobin concentration after Dex-BTC-Hb or stroma-free hemoglobin administration decreased significantly 120 min after IET. In presence of cytochalasin D, plasma hemoglobin concentration stayed constant in Dex-BTC-Hb-treated animals but not in stroma-free hemoglobin-treated animals. cytochalasin D inhibits the endocytosis in case of Dex-BTC-Hb but not in case of stroma-free hemoglobin. This would be due to the molecular weight of cell-free hemoglobin. Based on these data, we suggest that endocytosis is one of the mechanisms by which cell-free hemoglobin with high molecular weight penetrated inside vascular endothelial cells. This endocytosis would have an impact on induced hypertension.
 ...
PMID:[Potential mechanism of dextran-conjugated hemoglobin penetration inside arterial wall]. 1706 52

Specific members of the inward rectifier potassium (Kir) channel family are postulated drug targets for a variety of disorders, including hypertension, atrial fibrillation, and pain. For the most part, however, progress toward understanding their therapeutic potential or even basic physiological functions has been slowed by the lack of good pharmacological tools. Indeed, the molecular pharmacology of the inward rectifier family has lagged far behind that of the S4 superfamily of voltage-gated potassium (Kv) channels, for which a number of nanomolar-affinity and highly selective peptide toxin modulators have been discovered. The bee venom toxin tertiapin and its derivatives are potent inhibitors of Kir1.1 and Kir3 channels, but peptides are of limited use therapeutically as well as experimentally due to their antigenic properties and poor bioavailability, metabolic stability and tissue penetrance. The development of potent and selective small-molecule probes with improved pharmacological properties will be a key to fully understanding the physiology and therapeutic potential of Kir channels. The Molecular Libraries Probes Production Center Network (MLPCN) supported by the National Institutes of Health (NIH) Common Fund has created opportunities for academic scientists to initiate probe discovery campaigns for molecular targets and signaling pathways in need of better pharmacology. The MLPCN provides researchers access to industry-scale screening centers and medicinal chemistry and informatics support to develop small-molecule probes to elucidate the function of genes and gene networks. The critical step in gaining entry to the MLPCN is the development of a robust target- or pathway-specific assay that is amenable for high-throughput screening (HTS). Here, we describe how to develop a fluorescence-based thallium (Tl(+)) flux assay of Kir channel function for high-throughput compound screening. The assay is based on the permeability of the K(+) channel pore to the K(+) congener Tl(+). A commercially available fluorescent Tl(+) reporter dye is used to detect transmembrane flux of Tl(+) through the pore. There are at least three commercially available dyes that are suitable for Tl(+) flux assays: BTC, FluoZin-2, and FluxOR. This protocol describes assay development using FluoZin-2. Although originally developed and marketed as a zinc indicator, FluoZin-2 exhibits a robust and dose-dependent increase in fluorescence emission upon Tl(+) binding. We began working with FluoZin-2 before FluxOR was available and have continued to do so. However, the steps in assay development are essentially identical for all three dyes, and users should determine which dye is most appropriate for their specific needs. We also discuss the assay's performance benchmarks that must be reached to be considered for entry to the MLPCN. Since Tl(+) readily permeates most K(+) channels, the assay should be adaptable to most K(+) channel targets.
 ...
PMID:High-throughput screening for small-molecule modulators of inward rectifier potassium channels. 2338 7